LivaNova (LIVN) Tops Q3 Earnings and Revenue Estimates
LivaNova (LIVN) came out with quarterly earnings of $1.11 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.9 per share a year ago.
Is LivaNova (LIVN) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
LivaNova: Robust Fundamentals, Long-Term Growth Potential
LivaNova remains a 'BUY' with a raised price target of $61/share, reflecting strong recent results and long-term growth potential. LIVN delivered double-digit revenue growth, improved margins, and raised guidance, driven by Cardiopulmonary and Neuromodulation segment performance. Despite a 20% short-term return, I see further upside due to robust fundamentals, market expansion, and clinical milestones supporting the investment thesis.
Should Value Investors Buy LivaNova (LIVN) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
LivaNova PLC (LIVN) Q2 2025 Earnings Call Transcript
LivaNova PLC (NASDAQ:LIVN ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Ahmet Tezel - Chief Innovation Officer Alex Shvartsburg - Chief Financial Officer Briana Gotlin - Vice President of Investor Relations Stephanie Bolton - President of Global Epilepsy Vladimir A. Makatsaria - CEO & Director Conference Call Participants Adam Carl Maeder - Piper Sandler & Co., Research Division David Harrison Roman - Goldman Sachs Group, Inc., Research Division David Kenneth Rescott - Robert W.
LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates
LivaNova (LIVN) came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.93 per share a year ago.
LivaNova: The Sell-Off Is Excessive Here
LivaNova offers strong medtech upside with market-leading positions in cardiac surgery and neuromodulation, but lacks a dividend yield. Recent results show double-digit organic growth, margin expansion, and a positive sales trajectory, especially in Cardiopulmonary. Valuation is attractive: at a discounted 17x P/E, I see 20%+ annual upside and limited downside risk at current prices.
LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates
LivaNova (LIVN) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.73 per share a year ago.
LivaNova (LIVN) Tops Q4 Earnings Estimates
LivaNova (LIVN) came out with quarterly earnings of $0.81 per share, beating the Zacks Consensus Estimate of $0.80 per share. This compares to earnings of $0.87 per share a year ago.
Wall Street Analysts Predict a 37.2% Upside in LivaNova (LIVN): Here's What You Should Know
The mean of analysts' price targets for LivaNova (LIVN) points to a 37.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
LivaNova's OSPREY Sleep Apnea Trail on aura6000 Meets Primary Endpoint
LIVN's aura6000 significantly increases responder rates. The device also reduces AHI and ODI levels.
LivaNova (LIVN) Upgraded to Strong Buy: What Does It Mean for the Stock?
LivaNova (LIVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
